Kota Semarang

Researchers are evaluating whether the medicine tenecteplase helps adults recover from an acute ischemic stroke when given more than 4.5 hours after they were last seen well. This study focuses on people who had a stroke caused by a clot blocking blood flow in the brain and who have imaging showing brain tissue that can still be saved. Participants should not be planning to receive a procedure to remove the clot and must have a pre-stroke disability level of 0 or 1 on the modified Rankin Scale. Participants are randomly placed into two groups. One group receives a single injection of tenecteplase into a vein, while the other group receives standard medical care. The study includes adults aged 18 and over who had an acute stroke or woke up with stroke symptoms more than 4.5 hours ago. Imaging with MRI or CT is used to confirm eligibility. The study lasts about three months, starting with a hospital stay of about one week. During the study, participants have seven clinical examinations or visits to monitor their recovery and health. The last two visits may be done from home to allow remote assessments. Researchers use the modified Rankin Scale to measure disability or dependence in daily activities at 90 days after treatment. They also monitor for any side effects or health changes to compare the effects of tenecteplase against standard care.

Researchers are studying adults with Acute Decompensated Heart Failure (ADHF) to see if adding oral acetazolamide to intravenous furosemide helps reduce fluid overload more effectively. This Phase 4, randomized, double-blind study compares the combined treatment to furosemide with a placebo. The goal is to evaluate whether oral acetazolamide can improve decongestion success, increase urine output, lower NT pro BNP levels, and maintain safety. Participants will be randomly assigned to one of two groups: one receiving intravenous furosemide plus oral acetazolamide, and the other receiving intravenous furosemide plus an oral placebo. Treatment lasts up to 3 days, with the expectation that the combination therapy will lead to quicker fluid reduction and a shorter overall treatment duration. During the study, patients will be monitored for successful decongestion within 3 days, changes in urinary output, and NT pro BNP levels. Safety will be assessed throughout. Participants must provide informed consent and meet specific clinical criteria related to heart failure and volume overload. The study takes place in hospitals in Indonesia and tracks outcomes closely during the treatment period.

The HYIMPACT study is a large, observational research project across seven Asian countries designed to understand how Nebilet (nebivolol) works in people with high blood pressure, also called hypertension. It focuses on how Nebilet affects blood pressure control over time, treatment adherence, quality of life, prescription habits, and heart-related outcomes. The study includes about 5,000 adults with newly diagnosed or uncontrolled hypertension, some of whom may have other heart-related conditions. Participants will either start Nebilet treatment or have been on it for no more than two weeks before joining. They will be observed regularly for up to three years, with blood pressure measurements taken at baseline, 12, 24, and 36 months. The study also compares Nebilet used alone versus in combination with other treatments, and examines the relationship between blood pressure readings taken at home and in the clinic. Throughout the study, patients will have their blood pressure monitored, complete questionnaires about medication adherence and quality of life, and provide health information including cardiovascular risk factors and lab test results when available. Researchers will track major heart events like heart attacks and strokes, and record any side effects. Data will be collected electronically to ensure quality and consistency, helping to provide real-world insights about Nebilet's role in managing hypertension over time.

Researchers are evaluating the effects of synbiotic supplementation on patients with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD), a condition linked to metabolic problems such as obesity, diabetes, and liver fat accumulation not caused by alcohol. This study aims to investigate changes in metabolic profiles, insulin levels, TNF-alpha (a marker of inflammation), and gut microbiota in MAFLD patients after taking synbiotics. MAFLD involves complex factors including mitochondrial dysfunction, oxidative stress, and gut microbiota imbalance, which may contribute to liver damage and inflammation. Participants will be divided into two groups: one receiving a synbiotic supplement called RILLUS and the other receiving a placebo, both produced by Kalbe Farma. The dosage is two tablets daily for 12 weeks. Patients will visit the hospital every 28 days over approximately 4 months for follow-up and monitoring. They will also keep a logbook to record supplement intake and food consumption to track adherence and dietary changes during the study. Throughout the study, participants will undergo assessments including hematology tests, metabolic profiling, insulin and TNF-alpha measurements, and C-reactive protein (CRP) levels after 3 months. Researchers will analyze these markers to evaluate changes due to the synbiotic supplementation. The study also involves monitoring gut microbiota composition to understand its role in MAFLD. Safety and compliance will be closely observed during the follow-up visits.

Researchers are investigating the relationship between a visual echocardiographic scoring system, called the visual mitral and tricuspid (VMT) score, and clinical outcomes in patients with acute decompensated heart failure. The study uses secondary data collected from hospital registries, including demographic information, clinical presentations, laboratory results, and echocardiographic findings from patients diagnosed with this condition. Analysis is performed using IBM SPSS Statistics software to understand the associations between the scoring system and patient outcomes. The study does not involve new treatments or interventions but relies on reviewing existing medical records and echocardiographic machine databases. Data are gathered retrospectively from hospitalized patients who meet the study criteria. No additional procedures or therapies are applied as part of the research. Participants' data are evaluated based on hospital registry records during their hospitalization, with mortality during the hospital stay (up to one week) serving as a primary outcome measure. Researchers assess clinical and echocardiographic data to understand prognosis and outcomes in this patient group. The study focuses on data analysis without active follow-up or intervention periods.

Researchers are evaluating the effect of low-level tragus stimulation (LLTS) on heart function in patients with ST-segment Elevation Myocardial Infarction (STEMI) who undergo primary percutaneous coronary intervention (PPCI). This study aims to understand whether LLTS can change the left ventricular ejection fraction, wall motion score index, and diastolic dysfunction compared to a sham control. It also assesses the safety of LLTS in this patient group. Participants are divided into two groups: a treatment group receiving LLTS using the Parasym Neuromodulation Device applied to the left tragus for 60 minutes, and a control group receiving a sham procedure where the device lead is implanted but no stimulation is given for the same duration. Both groups undergo transthoracic echocardiographic examinations before and after PPCI to monitor changes. During the study, researchers will measure the left ventricular ejection fraction before PPCI, one day after, and 30 days post-PPCI. Other assessments include echocardiographic parameters related to heart wall motion and diastolic function. Safety and effects of the LLTS device are monitored throughout the study, which includes scheduled heart ultrasound scans and clinical evaluations over a 30-day follow-up period.

Researchers are studying the effects of low level tragus stimulation (LLTS) on heart rate variability, neutrophil-lymphocyte ratio, and major adverse cardiovascular events in patients with ST-segment Elevation Myocardial Infarction (STEMI). The trial aims to determine if LLTS can influence heart rate variability ratios, reduce inflammatory markers, and decrease serious complications such as mortality, reinfarction, stroke, lethal arrhythmia, acute lung edema, and cardiogenic shock compared to a sham control. Participants will be divided into two groups: a treatment group receiving LLTS via the Parasym Neuromodulation Device applied to the left tragus for 60 minutes, and a sham control group receiving device implantation without stimulation for the same duration. Both groups will undergo laboratory tests and heart rate variability measurements using the WeCardio device before and after Primary Percutaneous Coronary Intervention (PPCI). During the study, participants will have assessments including laboratory examinations and heart rate variability measurements before and after PPCI. Researchers will monitor major adverse cardiovascular events during hospitalization for up to one week to evaluate safety and effects of LLTS. The study includes adult participants aged 18 to 70 years with recent STEMI and stable clinical conditions at presentation.

Researchers are evaluating the ability of the anion gap, a blood test measurement, to predict major heart problems in patients who have experienced ST-segment elevation myocardial infarction (STEMI). This study uses hospital registry data from patients diagnosed with STEMI who received primary percutaneous coronary intervention (PPCI). The data includes patient demographics, clinical presentation, lab results, and angiography findings, which are analyzed to understand the prognostic value of the anion gap. Patients had their blood drawn before PPCI to measure the anion gap as part of the diagnostic testing. The study retrospectively reviews medical records from the hospital registry to gather all relevant information. There are no additional treatment groups; instead, the focus is on analyzing existing data collected during the patients' hospital stay. Participants' data is reviewed to track major adverse cardiovascular events (MACE) during hospitalization, up to one week after PPCI. Researchers collect and analyze information from medical records to evaluate the relationship between anion gap levels and cardiac outcomes. The study involves adults aged 18 to 70 years diagnosed with STEMI who underwent PPCI, ensuring thorough monitoring of heart events during the short hospital stay.

Researchers are evaluating how the anion gap can predict mortality in patients diagnosed with acute pulmonary embolism. This condition involves a blockage in the lungs' arteries, and the study aims to understand if the anion gap from laboratory tests can help assess risk of death during hospitalization. The study uses data collected from hospital records of patients diagnosed with acute pulmonary embolism confirmed by CT scans. Information includes demographics, clinical signs, lab results, and imaging findings. The analysis is performed using specialized statistical software to examine the relationship between the anion gap and patient outcomes. Participants' data come from hospital registries, focusing on in-hospital mortality occurring within one week of admission. Researchers review medical records and collect relevant clinical and laboratory information. The main outcome measured is death during hospitalization. This research relies on existing patient data and does not involve new treatments or interventions.

This research aims to evaluate and confirm the usefulness of a new Morphology-Voltage-P-wave Score (MVP Score) in detecting left ventricular diastolic dysfunction in patients with hypertension. The study focuses on adults aged 18 to 70 years who have essential hypertension and investigates how well this score identifies heart function issues related to diastolic dysfunction. Participants will undergo transthoracic echocardiography, a heart ultrasound test, to assess their diastolic function. Researchers will collect various data including demographic details, clinical information, laboratory results, and echocardiography findings. Two investigators will independently gather this information for analysis using specialized statistical software. During the study, participants will be monitored for diastolic dysfunction within one week. The researchers will analyze the collected data to validate the MVP Score's diagnostic accuracy. This process involves detailed heart assessments and thorough data review to understand the score's ability to identify diastolic problems in hypertensive patients.